SMS Pharmaceuticals Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/55ezf50mlw03febk3caq1bpg.pdf

Key Takeaways


The ARV Cliff & Diversification

Vamsi Krishna Potluri: "That particular product's contribution is around 42% in the last Q1 FY22 actually. Q1 FY22, that was around 42% was the contribution of that particular product. So, we want to, you know, more... decentralize our revenue, and we want to go in a different direction."

Ibuprofen: The FY24 Anchor

Vamsi Krishna Potluri: "We have developed the product and process and our engineering has been done in such a way that we will be competing in the market. So, as of now there is, I mean, obviously, there is price pressure, obviously, higher price. All of us are happy. But still we are with the current price also we will be able to compete in the market."

JV Portfolio: Launches Converting to Revenue


VKT: Early-Stage ANDA Play


Industry Context & Margin Dynamics

Vamsi Krishna Potluri: "The industry is sitting on stocks. So, if you see the stock inventory level of almost all the major companies, you see the inventory level, even including our company, has grown decently. The reason is because the movement of a product in the market is less. So, in order to compensate the movement, I think, you know, people are going down on the price, and they are sacrificing the margins in order to move the product that is sitting in the inventory."

R&D & New Product Strategy


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA turnaroundTurn EBITDA positiveBy end of Q2 FY23
PAT turnaroundTurn PAT positiveBy end of FY23
Ibuprofen full commercial launchFull-fledged commercial launch post customer qualification and PASBy Q4 FY23
Ibuprofen capacity utilizationExit at 70–80% run rateBy Q4 FY23
Ibuprofen FY24 revenue contribution35–40% of top lineFY24
VKT ANDA filingsFile two more ANDAs (filings, not approvals)By end of FY23
Sitagliptin FY23 sales₹70–80 croreFY23
ARV tender claritySome clarity from partners on forecastingPossibly by next quarter

Key Metrics

MetricQ1 FY23
Revenue₹9.86 cr (VKT only), sequential improvement with turnaround at EBITDA level
EBITDATurnaround at EBITDA level on sequential basis
VKT net loss₹7.02 cr
R&D expense~4% of revenue in FY22, planned growth of ~20% in FY23
Tenofovir revenue contributionHardly 2%, down from 42% in Q1 FY22
Anti-migraine revenue contributionRoughly 30%
Ibuprofen revenue contributionLess than 10%
Ibuprofen capacity utilization22%
Ibuprofen current priceLess than $10 per kilo, management believes prices have bottomed out
JV revenue contribution (current FY)About 11%
JV revenue contribution (expected)15% to 25% of top line going forward
SMS stake in JV45%
Total inventory₹275 cr approximately
WIP and finished goods inventory₹150 cr
Raw materials inventory₹125 cr
Sitagliptin capacity10 to 15 metric tons per month
Sitagliptin FY23 sales target₹70–80 cr (per an analyst's math)
Sitagliptin market share targetAt least 20% of ₹500 cr market (per an analyst's math)
VKT ANDAs6 currently, 2 more to be filed in FY23
Non-ARV commercial launches in FY223 products
Typical annual price erosion (old products)5% to 8%
Ibuprofen Q4 FY23 capacity utilization target70% to 80% run rate
Ibuprofen FY24 revenue contribution target35% to 40% of top line